EPO and anemia (phenotype): It has been reported that matrix-embedded MSCs, genetically modified to produce erythropoietin (EPO) and subcutaneously inoculated in a mouse model of anemia, supported the release of the protein into the bloodstream for a sustained pharmacological effect [26, 27].